Influence of molecular genetics in Vogt-Koyanagi-Harada disease

Journal of Ophthalmic Inflammation and Infection

Volumn 4, Issue 1, 2014, Pages 1-12

  Ng, Joanne Y W ^a   Luk, Fiona OJ ^a   Lai, Timothy Y Y ^a   Pang, Chi Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Genetics; Human leukocyte antigen; Interleukins; Single nucleotide polymorphisms; Vogt Koyanagi Harada disease

Indexed keywords

COMPLEMENT FACTOR H; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 27; JANUS KINASE 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOPONTIN; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; DISEASE COURSE; EMBASE; GENE CLUSTER; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; IMMUNE RESPONSE; MEDLINE; MOLECULAR GENETICS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PUBLICATION; VOGT KOYANAGI SYNDROME;

EID: 84923382394     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1186/s12348-014-0020-1     Document Type: Article

References (161)

1. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S (2000) Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 165:7323–7329
2. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131:647–652
3. Kitamura M, Takami K, Kitaichi N, Namba K, Kitamei H, Kotake S, Ohno S (2005) Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada's disease. Am J Ophthalmol 139:1080–1085, doi:10.1016/j.ajo.2005.01.046
4. Tabbara KF, Chavis PS, Freeman WR (1998) Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand 76:723–726
5. Wang Y, Chan CC (2014) Gender differences in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. J Ophthalmol 2014:157803, doi:10.1155/2014/157803
6. Yang P, Zhang Z, Zhou H, Li B, Huang X, Gao Y, Zhu L, Ren Y, Klooster J, Kijlstra A (2005) Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res 30:943–948, doi:10.1080/02713680500263606
7. Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39:265–292
8. Yamaki K, Hara K, Sakuragi S (2005) Application of revised diagnostic criteria for Vogt-Koyanagi-Harada disease in Japanese patients. Jpn J Ophthalmol 49:143–148, doi:10.1007/s10384-004-0165-9
9. Sasamoto Y, Ohno S, Matsuda H (1990) Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 201:162–167
10. Rubsamen PE, Gass JD (1991) Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 109:682–687
11. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA (2006) Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 142:119–124, doi:10.1016/j.ajo.2006.02.049
12. Chee SP, Luu CD, Cheng CL, Lim WK, Jap A (2005) Visual function in Vogt-Koyanagi-Harada patients. Graefes Arch Clin Exp Ophthalmol 243:785–790, doi:10.1007/s00417-005-1156-3
13. Lai TY, Chan RP, Chan CK, Lam DS (2009) Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond) 23:543–548, doi:10.1038/eye.2008.89
14. Rao NA (2007) Pathology of Vogt-Koyanagi-Harada disease. Int Ophthalmol 27:81–85, doi:10.1007/s10792-006-9029-2
15. Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:607–614
16. Bassili SS, Peyman GA, Gebhardt BM, Daun M, Ganiban GJ, Rifai A (1996) Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi-Harada syndrome. Retina 16:160–161
17. Sugita S, Takase H, Kawaguchi T, Taguchi C, Mochizuki M (2007) Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol 27:87–95, doi:10.1007/s10792-006-9020-y
18. Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M (2013) Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 12:1033–1038, doi:10.1016/j.autrev.2013.01.004
19. Otani S, Sakurai T, Yamamoto K, Fujita T, Matsuzaki Y, Goto Y, Ando Y, Suzuki S, Usui M, Takeuchi M, Kawakami Y (2006) Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 90:773–777, doi:10.1136/bjo.2005.086520
20. Klein J, Sato A (2000) The HLA system: first of two parts. New Eng J Med 343:702–709
21. Shiina T, Inoko H, Kulski JK (2004) An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 64:631–649, doi:10.1111/j.1399-0039.2004.00327.x
22. Stastny P (1978) Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 298:869–871, doi:10.1056/nejm197804202981602
23. McMichael AJ, Sasazuki T, McDevitt HO, Payne RO (1977) Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum 20:1037–1042
24. Islam SM, Numaga J, Fujino Y, Hirata R, Matsuki K, Maeda H, Masuda K (1994) HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 35:3890–3896
25. Zhang XY, Wang XM, Hu TS (1992) Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 113:567–572
26. Tagawa Y, Sugiura S, Yakura H, Wakisaka A, Aizawa M (1976) Letter: HLA and Vogt-Koyanagi-Harada syndrome. N Engl J Med 295:173
27. Davis JL, Mittal KK, Freidlin V, Mellow SR, Optican DC, Palestine AG, Nussenblatt RB (1990) HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology 97:1137–1142
28. Shindo Y, Inoko H, Yamamoto T, Ohno S (1994) HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol 78:223–226
29. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H (1994) Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada's disease. Hum Immunol 39:169–176
30. Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, Forster DJ, Rao NA, Terasaki PI (1995) Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology 102:1012–1015
31. Arellanes-Garcia L, Bautista N, Mora P, Ortega-Larrocea G, Burguet A, Gorodezky C (1998) HLA-DR is strongly associated with Vogt-Koyanagi-Harada disease in Mexican Mestizo patients. Ocul Immunol Inflamm 6:93–100
32. Levinson RD, See RF, Rajalingam R, Reed EF, Park MS, Rao NA, Holland GN (2004) HLA-DRB1 and -DQB1 alleles in Mestizo patients with Vogt-Koyanagi-Harada's disease in Southern California. Hum Immunol 65:1477–1482, doi:10.1016/j.humimm.2004.07.236
33. Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, Pirraglia MP (1996) Vogt-Koyanagi-Harada disease and HLA type in Italian patients. Am J Ophthalmol 122:889–891
34. Goldberg AC, Yamamoto JH, Chiarella JM, Marin ML, Sibinelli M, Neufeld R, Hirata CE, Olivalves E, Kalil J (1998) HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease. Hum Immunol 59:183–188
35. Kim MH, Seong MC, Kwak NH, Yoo JS, Huh W, Kim TG, Han H (2000) Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol 129:173–177
36. Iqniebi A, Gaafar A, Sheereen A, Al-Suliman A, Mohamed G, Al-Hussein K, Tabbara KF (2009) HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis 15:1876–1880
37. Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K (1994) Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 35:752–756
38. Damico FM, Cunha-Neto E, Goldberg AC, Iwai LK, Marin ML, Hammer J, Kalil J, Yamamoto JH (2005) T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis. Invest Ophthalmol Vis Sci 46:2465–2471, doi:10.1167/iovs.04-1273
39. Nomura S, Matsuzaki T, Ozaki Y, Yamaoka M, Yoshimura C, Katsura K, Xie GL, Kagawa H, Ishida T, Fukuhara S (1998) Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 91:3616–3622
40. Alaez C, Flores AH, Concha del Rio LE, Munguia A, Rodriguez A, Garcia D, Arellanes L, Gorodezky C (2011) Major histocompatibility complex and strong human leukocyte antigen-DRB1 and gender association with Vogt-Koyanagi-Harada syndrome in Mexican Mestizos. Hum Immunol 72:1198–1203, doi:10.1016/j.humimm.2011.09.002
41. Tiercy JM, Rathinam SR, Gex-Fabry M, Baglivo E (2010) A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients. Mol Vis 16:353–358
42. Jaini R, Kaur G, Mehra NK (2002) Heterogeneity of HLA-DRB1*04 and its associated haplotypes in the North Indian population. Hum Immunol 63:24–29
43. Gupta A, Kamal S, Gupta V, Bambery P, Kaura B (2007) HLA typing in Vogt-Koyanagi-Harada syndrome in North Indian patients. Ocul Immunol Inflamm 15:89–97, doi:10.1080/09273940601186727
44. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, Wang Y, Walunas T, Bluestone J, Listman J, Finn PW (1996) Regulation of CTLA-4 expression during T cell activation. J Immunol 156:4154–4159
45. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF et al (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506–511, doi:10.1038/nature01621
46. Harbo HF, Celius EG, Vartdal F, Spurkland A (1999) CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 53:106–110
47. Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452–455, doi:10.1007/s00439-002-0807-2
48. Gonzalez-Escribano MF, Rodriguez R, Valenzuela A, Garcia A, Garcia-Lozano JR, Nunez-Roldan A (1999) CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Tissue Antigens 53:296–300
49. Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, Jie Q, Fang D, Ningli L, Xinghai H, Daming R (2005) Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet 13:823–828, doi:10.1038/sj.ejhg.5201423
50. Deng L, Zhou H, Yang J, Xiao J, Wang B, Wang L, Ou X, Feng Y (2013) CTLA-4 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. Int J Clin Exp Pathol 6:2548–2553
51. Knight AK, Serrano D, Tomer Y, Cunningham-Rundles C (2007) CTLA-4 gene exon-1 +49 A/G polymorphism: lack of association with autoimmune disease in patients with common variable immune deficiency. J Clin Immunol 27:95–100, doi:10.1007/s10875-006-9049-8
52. Yanagawa T, Maruyama T, Gomi K, Taniyama M, Kasuga A, Ozawa Y, Terauchi M, Hirose H, Maruyama H, Saruta T (1999) Lack of association between CTLA-4 gene polymorphism and IDDM in Japanese subjects. Autoimmunity 29:53–56
53. Du L, Yang P, Hou S, Lin X, Zhou H, Huang X, Wang L, Kijlstra A (2008) Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol 127:43–48, doi:10.1016/j.clim.2008.01.004
54. Jha P, Sohn JH, Xu Q, Nishihori H, Wang Y, Nishihori S, Manickam B, Kaplan HJ, Bora PS, Bora NS (2006) The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 47:1030–1038
55. Manickam B, Jha P, Matta B, Liu J, Bora PS, Bora NS (2011) Inhibition of complement alternative pathway suppresses experimental autoimmune anterior uveitis by modulating T cell responses. J Biol Chem 286:8472–8480
56. Yang MM, Lai TY, Tam PO, Chiang SW, Chan CK, Luk FO, Ng TK, Pang CP (2011) CFH 184G as a genetic risk marker for anterior uveitis in Chinese females. Mol Vis 17:2655–2664
57. Yang MM, Lai TY, Tam PO, Chiang SW, Chan CK, Luk FO, Ng TK, Pang CP (2012) Complement factor H and interleukin gene polymorphisms in patients with non-infectious intermediate and posterior uveitis. Mol Vis 18:1865–1872
58. Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G (1990) Serum interleukin 2-receptor levels in uveitis. Curr Eye Res 9:25–29
59. Lacomba MS, Martin CM, Chamond RR, Galera JM, Omar M, Estevez EC (2000) Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 118:768–772
60. Liu L, Xu Y, Wang J, Li H (2009) Upregulated IL-21 and IL-21 receptor expression is involved in experimental autoimmune uveitis (EAU). Mol Vis 15:2938–2944
61. Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol 17:1428–1429
62. Charteris DG, Lightman SL (1994) Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis. Br J Ophthalmol 78(10):786–790
63. Cordeiro CA, Moreira PR, Costa GC, Dutra WO, Campos WR, Orefice F, Teixeira AL (2008) Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol Vis 14:1845–1849
64. Trinchieri G (1993) Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335–338
65. Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974
66. Yanagihori H, Oyama N, Nakamura K, Mizuki N, Oguma K, Kaneko F (2006) Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: an involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J Invest Dermatol 126:1534–1540
67. Li X, Bai L, Fang J, Hou S, Zhou Q, Yu H, Kijlstra A, Yang P (2014) Genetic variations of IL-12B, IL-12Rbeta1, IL-12Rbeta2 in Behcet's disease and VKH syndrome. PLoS One 9:98373, doi:10.1371/journal.pone.0098373
68. Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, Chen L, Zhou H, Huang X, Kijlstra A (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119:1218–1224, doi:10.1016/j.jaci.2007.01.010
69. Shu Q, Yang P, Hou S, Li F, Chen Y, Du L, Jiang Z (2010) Interleukin-17 gene polymorphism is associated with Vogt-Koyanagi-Harada syndrome but not with Behcet's disease in a Chinese Han population. Hum Immunol 71:988–991, doi:10.1016/j.humimm.2010.06.020
70. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744–748, doi:10.1038/nature01355
71. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198:1951–1957, doi:10.1084/jem.20030896
72. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240, doi:10.1084/jem.20041257
73. Jiang Z, Yang P, Hou S, Li F, Zhou H (2010) Polymorphisms of IL23R and Vogt-Koyanagi-Harada syndrome in a Chinese Han population. Hum Immunol 71:414–417, doi:10.1016/j.humimm.2010.01.026
74. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13:711–718
75. Cua DJ, Kastelein RA (2006) TGF-beta, a 'double agent' in the immune pathology war. Nat Immunol 7:557–559, doi:10.1038/ni0606-557
76. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677–688
77. Parham P (2005) Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 42:459–462, doi:10.1016/j.molimm.2004.07.027
78. Boyton RJ, Altmann DM (2007) Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 149:1–8, doi:10.1111/j.1365-2249.2007.03424.x
79. Sheereen A, Gaafar A, Iqneibi A, Eldali A, Tabbara KF, Adra C, Al-Hussein K (2011) A study of KIR genes and HLA-C in Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis 17:3523–3528
80. Levinson RD, Okada AA, Ashouri E, Keino H, Rajalingam R (2010) Killer cell immunoglobulin-like receptor gene-cluster 3DS1-2DL5-2DS1-2DS5 predisposes susceptibility to Vogt-Koyanagi-Harada syndrome in Japanese individuals. Hum Immunol 71:192–194, doi:10.1016/j.humimm.2009.11.001
81. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895
82. Rui Y, Honjo T, Chikuma S (2013) Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proc Natl Acad Sci USA 110:16073–16078, doi:10.1073/pnas.1315828110
83. Newby PR, Roberts-Davies EL, Brand OJ, Heward JM, Franklyn JA, Gough SC, Simmonds MJ (2007) Tag SNP screening of the PDCD1 gene for association with Graves' disease. Clin Endocrinol (Oxf) 67:125–128, doi:10.1111/j.1365-2265.2007.02848.x
84. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST (2003) Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62:492–497
85. Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH, Kim YH, Kim KS, Hong SJ, Yoo MC, Yang HI (2006) Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 8:R163, doi:10.1186/ar2071
86. Kong EK, Prokunina-Olsson L, Wong WH, Lau CS, Chan TM, Alarcon-Riquelme M, Lau YL (2005) A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 52:1058–1062, doi:10.1002/art.20966
87. Liu C, Jiang J, Gao L, Hu X, Wang F, Shen Y, Yu G, Zhao Z, Zhang X (2014) A promoter region polymorphism in PDCD-1 gene is associated with risk of rheumatoid arthritis in the Han Chinese population of southeastern China. Int J Genomics 2014:247637, doi:10.1155/2014/247637
88. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669, doi:10.1038/ng1020
89. Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F, Liz M, Martin J, Ordi J, Vicario JL, Gonzalez A (2004) Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum 50:2590–2597, doi:10.1002/art.20436
90. Velazquez-Cruz R, Orozco L, Espinosa-Rosales F, Carreno-Manjarrez R, Solis-Vallejo E, Lopez-Lara ND, Ruiz-Lopez IK, Rodriguez-Lozano AL, Estrada-Gil JK, Jimenez-Sanchez G, Baca V (2007) Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet 15:336–341, doi:10.1038/sj.ejhg.5201767
91. Thorburn CM, Prokunina-Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon-Riquelme ME, Criswell LA (2007) Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun 8:279–287, doi:10.1038/sj.gene.6364383
92. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Maurer M, Wiendl H (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58:50–57, doi:10.1002/ana.20514
93. Abelson AK, Johansson CM, Kozyrev SV, Kristjansdottir H, Gunnarsson I, Svenungsson E, Jonsen A, Lima G, Scherbarth HR, Gamron S, Allievi A, Palatnik SA, Alvarellos A, Paira S, Graf C, Guilleron C, Catoggio LJ, Prigione C, Battagliotti CG, Berbotto GA, Garcia MA, Perandones CE, Truedsson L, Steinsson K, Sturfelt G, Pons-Estel B, Alarcon-Riquelme ME (2007) No evidence of association between genetic variants of the PDCD1 ligands and SLE. Genes Immun 8:69–74, doi:10.1038/sj.gene.6364360
94. Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, Chen CJ (2004) Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 50:770–775, doi:10.1002/art.20040
95. Iwamoto T, Ikari K, Inoue E, Toyama Y, Hara M, Yamanaka H, Tomatsu T, Momohara S, Kamatani N (2007) Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. J Hum Genet 52:557–560, doi:10.1007/s10038-007-0145-2
96. Asad S, Nikamo P, Torn C, Landin-Olsson M, Lernmark A, Alarcon-Riquelme M, Kockum I (2007) No evidence of association of the PDCD1 gene with type 1 diabetes. Diabet Med 24:1473–1477, doi:10.1111/j.1464-5491.2007.02297.x
97. Jiao Q, Liu C, Yang Z, Ding Q, Wang M, Li M, Zhu T, Qian H, Li W, Tu N, Fang F, Ye L, Zhao Z, Qian Q (2014) Upregulated PD-1 expression is associated with the development of systemic lupus erythematosus, but not the PD-1.1 allele of the PDCD1 gene. Int J Genomics 2014:950903
98. Meng Q, Liu X, Yang P, Hou S, Du L, Zhou H, Kijlstra A (2009) PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis 15:386–392
99. Bottini N, Peterson EJ (2014) Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu Rev Immunol 32:83–119, doi:10.1146/annurev-immunol-032713-120249
100. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36:337–338, doi:10.1038/ng1323
101. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK (2005) Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76:561–571, doi:10.1086/429096
102. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330–337, doi:10.1086/422827
103. Michou L, Lasbleiz S, Rat AC, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pierlot C, Glikmans E, Garnier S, Dausset J, Vaz C, Fernandes M, Petit-Teixeira E, Lemaire I, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, Lopes-Vaz A, Prum B, Bardin T, Dieude P, Cornelis F (2007) Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci USA 104:1649–1654, doi:10.1073/pnas.0610250104
104. Ichimura M, Kaku H, Fukutani T, Koga H, Mukai T, Miyake I, Yamada K, Koda Y, Hiromatsu Y (2008) Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population. Thyroid 18:625–630, doi:10.1089/thy.2007.0353
105. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75:504–507, doi:10.1086/423790
106. Horie Y, Kitaichi N, Katsuyama Y, Yoshida K, Miura T, Ota M, Asukata Y, Inoko H, Mizuki N, Ishida S, Ohno S (2009) Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients. Mol Vis 15:1115–1119
107. Zhang Q, Qi J, Hou S, Du L, Yu H, Cao Q, Zhou Y, Liao D, Kijlstra A, Yang P (2014) A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis. PLoS One 9:e96943, doi:10.1371/journal.pone.0096943
108. Heilmann K, Hoffmann U, Witte E, Loddenkemper C, Sina C, Schreiber S, Hayford C, Holzlohner P, Wolk K, Tchatchou E, Moos V, Zeitz M, Sabat R, Gunthert U, Wittig BM (2009) Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 13:1162–1174, doi:10.1111/j.1582-4934.2008.00428.x
109. Lund SA, Giachelli CM, Scatena M (2009) The role of osteopontin in inflammatory processes. J Cell Commun Signal 3:311–322, doi:10.1007/s12079-009-0068-0
110. Chu M, Yang P, Hu R, Hou S, Li F, Chen Y, Kijlstra A (2011) Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 52:7084–7089, doi:10.1167/iovs.11-7539
111. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289:2350–2354
112. Liu YC, Penninger J, Karin M (2005) Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol 5:941–952, doi:10.1038/nri1731
113. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coblyn J et al (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39:1477–1482, doi:10.1038/ng.2007.27
114. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, Wilson AG, Marinou I, Morgan A, Emery P, Carter A, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Strachan D, Worthington J (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39:1431–1433, doi:10.1038/ng.2007.32
115. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204, doi:10.1038/ng.311
116. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059–1061, doi:10.1038/ng.200
117. Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM, Guthridge JM, Alarcon-Riquelme ME, Anaya JM, Bae SC, Bang SY, Boackle SA, Brown EE, Petri MA, Gallant C, Ramsey-Goldman R, Reveille JD, Vila LM, Criswell LA, Edberg JC, Freedman BI, Gregersen PK, Gilkeson GS, Jacob CO, James JA, Kamen DL et al (2011) Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 43:253–258, doi:10.1038/ng.766
118. Li H, Liu Q, Hou S, Du L, Zhou Q, Zhou Y, Kijlstra A, Yang P (2013) TNFAIP3 gene polymorphisms in a Chinese Han population with Vogt-Koyanagi-Harada syndrome. PLoS One 8:e59515, doi:10.1371/journal.pone.0059515
119. Baugh JA, Bucala R (2002) Macrophage migration inhibitory factor. Crit Care Med 30:S27–35
120. Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 123:484–487, doi:10.1111/j.0022-202X.2004.23314.x
121. Sanchez E, Gomez LM, Lopez-Nevot MA, Gonzalez-Gay MA, Sabio JM, Ortego-Centeno N, de Ramon E, Anaya JM, Gonzalez-Escribano MF, Koeleman BP, Martin J (2006) Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 7:433–436, doi:10.1038/sj.gene.6364310
122. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, Hamanaka Y, Higaki S, Yanai H, Yoshida T, Hibi T, Okita K, Hinoda Y (2004) Association of the -173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 39:242–246, doi:10.1007/s00535-003-1284-7
123. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, Meazza C, De Benedetti F, Thomson W, Ray D (2004) A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 50:1604–1610, doi:10.1002/art.20178
124. Berdeli A, Ozyurek AR, Ulger Z, Gurses D, Levent E, Salar K, Gurpinar AR (2006) Association of macrophage migration inhibitory factor gene -173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis. Rheumatol Int 26:726–731, doi:10.1007/s00296-005-0062-7
125. Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M (2010) Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res 38:69–77
126. Kotake S, Kitaichi N, Ohno S (2002) Macrophage migration inhibitory factor in uveitis. Int Ophthalmol Clin 42:99–103
127. Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, Onoe K, Matsuda H, Nishihira J (1999) Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci 40:247–250
128. Zhang C, Liu S, Hou S, Lei B, Zheng X, Xiao X, Kijlstra A, Yang P (2013) MIF gene polymorphisms confer susceptibility to Vogt-Koyanagi-Harada syndrome in a Han Chinese population. Invest Ophthalmol Vis Sci 54:7734–7738, doi:10.1167/iovs.13-12187
129. Jimenez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, Garcia-Borron JC (1994) A new enzymatic function in the melanogenic pathway. The 5,6-dihydroxyindole-2-carboxylic acid oxidase activity of tyrosinase-related protein-1 (TRP1). J Biol Chem 269:17993–18000
130. Sturm RA, Teasdale RD, Box NF (2001) Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 277:49–62
131. Oetting WS (2000) The tyrosinase gene and oculocutaneous albinism type 1 (OCA1): a model for understanding the molecular biology of melanin formation. Pigment Cell Res 13:320–325
132. Sundaresan P, Sil AK, Philp AR, Randolph MA, Natchiar G, Namperumalsamy P (2004) Genetic analysis of oculocutaneous albinism type 1 (OCA1) in Indian families: two novel frameshift mutations in the TYR Gene. Mol Vis 10:1005–1010
133. Chaki M, Mukhopadhyay A, Chatterjee S, Das M, Samanta S, Ray K (2005) Higher prevalence of OCA1 in an ethnic group of eastern India is due to a founder mutation in the tyrosinase gene. Mol Vis 11:531–534
134. Horie Y, Takemoto Y, Miyazaki A, Namba K, Kase S, Yoshida K, Ota M, Hasumi Y, Inoko H, Mizuki N, Ohno S (2006) Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients. Mol Vis 12:1601–1605
135. Takase H, Futagami Y, Yoshida T, Kamoi K, Sugita S, Imai Y, Mochizuki M (2006) Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci 47:1557–1561, doi:10.1167/iovs.05-0836
136. Ohno S (1981) Immunological aspects of Behcet's and Vogt-Koyanagi-Harada's diseases. Trans Ophthalmol Soc UK 101(Pt 3):335–341
137. Horie Y, Kitaichi N, Takemoto Y, Namba K, Yoshida K, Hirose S, Hasumi Y, Ota M, Inoko H, Mizuki N, Ohno S (2007) Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease. Mol Vis 13:2334–2338
138. Gregersen PK (2007) Modern genetics, ancient defenses, and potential therapies. N Engl J Med 356:1263–1266, doi:10.1056/NEJMe078017
139. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16:208–214
140. Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, Fain PR, Spritz RA (2005) Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res 18:300–305
141. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216–1225
142. Horie Y, Saito W, Kitaichi N, Miura T, Ishida S, Ohno S (2011) Evaluation of NLRP1 gene polymorphisms in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 55:57–61, doi:10.1007/s10384-010-0887-9
143. Kandimalla ER, Zhu FG, Bhagat L, Yu D, Agrawal S (2003) Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem Soc Trans 31(Pt 3):654–658
144. Ito R, Ota M, Meguro A, Katsuyama Y, Uemoto R, Nomura E, Nishide T, Kitaichi N, Horie Y, Namba K, Ohno S, Inoko H, Mizuki N (2011) Investigation of association between TLR9 gene polymorphisms and VKH in Japanese patients. Ocul Immunol Inflamm 19:202–205, doi:10.3109/09273948.2011.553981
145. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441:231–234
146. Manel N, Unutmaz D, Littman DR (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9:641–649
147. O'Garra A, Stockinger B, Veldhoen M (2008) Differentiation of human T(H)-17 cells does require TGF-beta! Nat Immunol 9:588–590, doi:10.1038/ni0608-588
148. Chen Y, Yang P, Li F, Hou S, Jiang Z, Shu Q, Kijlstra A (2012) Association analysis of TGFBR3 gene with Vogt-Koyanagi-Harada disease and Behcet's disease in the Chinese Han population. Curr Eye Res 37:312–317, doi:10.3109/02713683.2011.635398
149. Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, Kapur R, Levy DE, Kansas GS, Kaplan MH (2007) Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 178:4901–4907
150. Hu K, Hou S, Li F, Xiang Q, Kijlstra A, Yang P (2013) JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population. Invest Ophthalmol Vis Sci 54:3360–3365, doi:10.1167/iovs.13-11615
151. Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, Gao XH, Chen HD, Pu XM, Wu RN, Liang CZ, Li JB, Gao TW, Zhang JZ, Wang XL, Wang J, Yang RY, Liang L, Yu JB, Zuo XB, Zhang SQ, Zhang SM, Chen G, Zheng XD, Li P, Zhu J, Li YW, Wei XD, Hong WS, Ye Y, Zhang Y et al (2010) Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 42:614–618, doi:10.1038/ng.603
152. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40:955–962, doi:10.1038/ng.175
153. Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, Ouwehand W, Strachan D, McArdle W, Lewis CM, Lobo A, Sanderson J, Jewell DP, Deloukas P, Mansfield JC et al (2009) Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136:523–529.e523
154. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P et al (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–514, doi:10.1038/ng.582
155. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, Yamazaki K, Hosono N, Myouzen K, Tsunoda T, Kamatani N, Furuichi T, Ikegawa S, Ohmura K, Mimori T, Matsuda F, Iwamoto T, Momohara S, Yamanaka H, Yamada R, Kubo M, Nakamura Y, Yamamoto K (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:515–519, doi:10.1038/ng.583
156. Chu X, Pan CM, Zhao SX, Liang J, Gao GQ, Zhang XM, Yuan GY, Li CG, Xue LQ, Shen M, Liu W, Xie F, Yang SY, Wang HF, Shi JY, Sun WW, Du WH, Zuo CL, Shi JX, Liu BL, Guo CC, Zhan M, Gu ZH, Zhang XN, Sun F, Wang ZQ, Song ZY, Zou CY, Sun WH, Guo T et al (2011) A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 43:897–901, doi:10.1038/ng.898
157. Popovici C, Zhang B, Gregoire MJ, Jonveaux P, Lafage-Pochitaloff M, Birnbaum D, Pebusque MJ (1999) The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93:1381–1389
158. Guasch G, Ollendorff V, Borg JP, Birnbaum D, Pebusque MJ (2001) 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. Mol Cell Biol 21:8129–8142, doi:10.1128/mcb.21.23.8129-8142.2001
159. Yan X, Habedanck R, Nigg EA (2006) A complex of two centrosomal proteins, CAP350 and FOP, cooperates with EB1 in microtubule anchoring. Mol Biol Cell 17:634–644, doi:10.1091/mbc.E05-08-0810
160. Yi X, Du L, Hou S, Li F, Chen Y, Kijlstra A, Yang P (2013) FGFR1OP tagSNP but not CCR6 polymorphisms are associated with Vogt-Koyanagi-Harada syndrome in Chinese Han. PLoS One 8:e69358, doi:10.1371/journal.pone.0069358
161. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES (2001) Linkage disequilibrium in the human genome. Nature 411:199–204, doi:10.1038/35075590